Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07117630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07117630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
September 25, 2025
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer